Breast Cancers
GI Cancers
Gynecologic Cancer
Immunology News
Multiple Myeloma
Head and Neck
Lung Cancers
Prostate Cancer
Kidney Cancer
Precision Medicine
Supportive Care
Soft Tissue Sarcoma
Giants Cancer Care

Ovarian Cancer Subtypes May Predict Response to Bevacizumab

Sean Dowdy, MD
Published Online: Monday, June 9, 2014

Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

Online CME Activities
Free CME from PER
Evolving Management Strategies for Triple-Negative Breast Cancer
Community Practice Connections™: Current and Emerging Strategies in the Management of Early Breast Cancer
Cancer Summaries and Commentaries™: Update from Vienna: Advances in the Treatment of Gastrointestinal Cancers
Advances in Targeted Therapy: The Emerging Role of PARP Inhibitors in the Treatment of Cancers
More Reading